by Written on behalf of Wise Health Law July 26, 2018 3 min read

A class action lawsuit filed by a group of patients in British Columbia against the federal minister of health alleges that the government’s decision not to cover the costs of a cystic fibrosis (CF) drug violates the Charter of Rights and Freedoms. The plaintiffs are seeking $60 million in damages for the denial of coverage.

The Drug: Orkambi

The drug in question, Orkambi, was approved for use in Canada in January 2016. It targets the underlying cause of CF and is intended to correct defective cystic fibrosis transmembrance conductance regulator (CFTR) proteins. In CF patients, the absence of CFTR results in thick, sticky, mucus in the lungs and other parts of the body. Orkambi is intended for CF patients (aged 12 and older) who have two copies of a specific mutation. There are approximately 1,550 patients in Canada who may be eligible to use this drug. The drug has had a positive impact on many CF patients. Melissa Verleg, a B.C. mother and one of the lead plaintiffs in the class action called the drug “life-changing”. Verleg told CBC News that the drug made it possible for her to get out of bed, feed her children, and take them to school, noting that “for the first time in a long time, I got to be a mother to .” Lila Zaharevia, the second lead plaintiff, says that Orkambi stopped years of steep decline in her health, which, at one point, looked like it would require a lung transplant. Like Verleg, she notes that the drug changed her life, saying that in the year prior to taking it she could “hardly walk between…classes without feeling short of breath.” Since then, Vertex Pharmaceuticals, the company who makes the drug has granted her access to it on compassionate grounds. The drug is expensive, costing about $170.54 per pill or about $250,000 annually, per patient. B.C. and other provinces currently do not provide coverage for this medication. While Orkambi has been approved for use by Health Canada, it is ultimately up to each province to decide what they will cover under provincial health plans, like OHIP. In making such decisions, the provinces take guidance from the Canadian Agency for Drugs and Technologies in Health (CADTH), a federal drug review body.

Coverage for the Drug

B.C. made the decision not to cover Orkambi in March 2017, claiming that it was “not-cost effective” given its price and the “modest improvement in lung function” that the government said it provided. An earlier review by the CADTH had made the same conclusion, noting that while two double-blind randomized controlled trials had shown statistically significant improvements in lung function, the level of improvement had “uncertain clinical significance”. Earlier this year, Verleg’s extended health plan also deemed Orkambi to be too expensive and did not provide coverage either. Verleg ceased use of the medication. Since then, she says that her lung function has become unstable and that she spends half of each day on IV antibiotics.

The Lawsuit

The lawsuit disputes the decisions of the CADTH and the B.C. government, claiming that Orkambi is medically necessary for the approximately 200 patients in B.C. who have the specific type of CF that the drug treats. It also claims that the failure to cover a medically necessary treatment violates the Charter rights of these patients. Beyond the financial relief requested, the suit also wants a more “transparent, objective and evidence-based system” for drug approval in Canada and wants B.C. to negotiate with Vertex. B.C. was chosen as the jurisdiction where the suit was launched because of successful Charter challenges in the province in the past, including related to medical assistance in dying (MAID). However, other provinces also do not provide coverage.

The Government’s Position

The B.C. Ministry of Health has said that it will not comment on the lawsuit, but did defend their original coverage decision, re-iterating that there is “insufficient evidence” that would justify paying the drugs high cost. It further noted that “this process ensures that important drug listing decisions are based on evidence-based, clinical analysis involving patient groups and are not the result of political lobbying”. The CADTH is currently re-reviewing the drug, after its manufacturer provided new evidence that the the B.C. government recommended be considered. The federal minister of health declined to comment. We will continue to follow developments in this matter and will provide updates as they become available. Wise Health Law was founded in 2013 by Valerie Wise and has offices in both Toronto and Oakville, Ontario. Our team of trusted health lawyers in health and administrative law, and focuses on helping health professionals, public hospitals, and national and provincial health professional associations, among others, find solutions to their legal and regulatory problems. With offices in both Toronto and Oakville, Ontario we are easily accessible. Contact us online, or at 416-915-4234for a consultation.


Also in Blog

Health Care Professionals in Ontario Begin the Restart

by Valerie Wise May 28, 2020 3 min read

The Chief Medical Officer of Health for Ontario has issued an updated Directive #2 (dated May 26, 2020) for Regulated Health Professionals in the province. 

Pursuant to the updated Directive #2, all deferred non-essential and elective services by health care providers may be gradually restarted – subject to the rest of the requirements set out in the Directive.

The updated Directive #2 does not provide particularly detailed guidance to health professionals on how to proceed, likely because it applies to such a broad spectrum of health care and health professionals. It does, however, provide some principles to assist health care providers in making decisions as we enter this transitional period.

International Medical Graduates Reinforcing the Healthcare Frontlines

by Mina Karabit May 25, 2020 2 min read

In addition to the mask and hand sanitizer shortages, Ontario’s response to COVID-19 highlights the need for more frontline health care workers. Each regulated health profession’s college responded differently, and we have discussed some of those changes in other posts to keep you apprised.

Today, we focus on the College of Physicians and Surgeons of Ontario (CPSO), who set out to increase the number of available and licenced physicians out on the frontlines through certificates of registration that authorize supervised practice of short duration. The temporary licences authorize practice for 30 days.  

Pharmacists’ Time-Limited Change in Scope of Practice During COVID-19

by Mina Karabit May 05, 2020 4 min read

Undoubtedly, COVID-19 has affected how health professionals practice. Pharmacists across the country are not only experiencing changes in how they practice (for example, accepting emailed prescriptions, where appropriate) but the scope of their practice as well. The latter change is not permanent, although the disruptions in practice may be felt long after the COVID-19 emergency subsides.

On March 19, 2020, Health Canada issued a short-term section 56(1) exemption under the Controlled Drugs and Substances Act (CDSA) that would authorize pharmacists to prescribe, sell, or provide controlled substances in limited circumstances, or transfer prescriptions for controlled substances (the CDSA Exemption).